Testing effectiveness (Phase 2)WithdrawnNCT03868423
What this trial is testing
Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers
Who this might be right for
Advanced Malignant NeoplasmALK Fusion Protein ExpressionALK Gene Amplification+8 more
Sameek Roychowdhury